Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Relay Therapeutics's Debt-to-EBITDA or its related term are showing as below:
RLAY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.47 Med: -0.14 Max: 0
Current: -0.1
RLAY's Debt-to-EBITDA is ranked worse than 100% of 297
companies
in the Biotechnology industry
Industry Median: 1.16
vs RLAY: -0.10
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Relay Therapeutics Debt-to-EBITDA Related Terms
Relay Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Relay Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RLAY vs CELC, VKTX, DYN: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Relay Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relay Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relay Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Relay Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Relay Therapeutics (RLAY) has a Debt-to-EBITDA of -0.09 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Relay Therapeutics. According to the industry distribution chart, Relay Therapeutics ranks #999999 out of 297 companies in the Biotechnology industry.
Is Relay Therapeutics' Debt-to-EBITDA too high?
Relay Therapeutics' current Debt-to-EBITDA is -0.09. Based on the distribution chart, Relay Therapeutics ranks #999999 out of 297 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Relay Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Relay Therapeutics' Debt-to-EBITDA compare to CELC and VKTX?
According to the Biotechnology industry distribution chart, Relay Therapeutics ranks #999999 out of 297 companies for Debt-to-EBITDA. This places Relay Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.16, based on 297 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Relay Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relay Therapeutics's current Debt-to-EBITDA is -0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relay Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Relay Therapeutics (RLAY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.80, compared to a current price of $20.08 — trading 428.4% above its estimated fair value. The current Debt-to-EBITDA is -0.09. Relay Therapeutics' overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Relay Therapeutics (RLAY), the current Debt-to-EBITDA is -0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relay Therapeutics (RLAY) Overvalued in 2026?
Based on GuruFocus' analysis, Relay Therapeutics stock appears to be overvalued.
The current stock price of $20.08 is trading 428.4% above its estimated GF Value™ of $3.80.
GuruFocus considers Relay Therapeutics to be Significantly Overvalued.
Key valuation signals for RLAY:
Debt-to-EBITDA: -0.09
GF Value™: $3.80 vs. price of $20.08 (428.4% above fair value)
No single metric tells the full story. See the RLAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
46GF Score
Get the complete analysis for RLAY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLAY has been successfully added to your 
